Brief: Rain Oncology Provides Company Update And Outlines Strategic Priorities Of Milademetan Clinical Programs
30/05/2023 13:51
May 30 (Reuters) - Rain Oncology Inc RAIN.O :
* RAIN ONCOLOGY PROVIDES COMPANY UPDATE AND OUTLINES
STRATEGIC
PRIORITIES OF MILADEMETAN CLINICAL PROGRAMS
* RAIN ONCOLOGY INC - OVERALL WORKFORCE REDUCTION OF
APPROXIMATELY
65% OF COMPANY'S EMPLOYEES
* RAIN ONCOLOGY INC - FOCUSED ON REDUCING ITS CASH BURN WITH
EXPECTATION TO EXTEND CASH RUNWAY TO YEAR-END 2026
* RAIN ONCOLOGY INC - YEAR-END 2023 CASH GUIDANCE OF $75-$80
MILLION, AND CASH RUNWAY TO YEAR-END 2026
* RAIN ONCOLOGY-PLANS TO SUSPEND ENROLLMENT IN ONGOING
MILADEMETAN
PHASE 2 MANTRA-2 BASKET TRIAL, TERMINATE PLANS FOR PHASE 1/2
MANTRA-4 COMBINATION TRIAL
Source text for Eikon: ID:nGNX3PJZXm
Further company coverage: RAIN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rain Oncology
See all newsBrief: Rain Enhancement Technologies Holdco - May Offer Up To $25 Million In Securities From Time To Time - SEC Filing
Brief: Rain Enhancement Technologies Holdco Inc - Q1 And Q2 2025 Financial Statements Should Not Be Relied Upon Due To Accounting Error - SEC Filing
Brief: Rain Oncology Pursuant To Proposed Deal With Pathos AI
Brief: Rain Oncology To Be Acquired By Pathos AI For $1.16 In Cash Per Share Plus Contingent Value Rights
Brief: Rain Oncology Q3 Net Income USD -7.034 Million